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Hepatitis C virus (HCV) is a pandemic disease aﬀecting an estimated 180 million individuals worldwide and infecting each year
another ∼3-4 million people making HCV a global public health issue. HCV is the main cause for chronic hepatitis, cirrhosis, and
hepatocellularcarcinoma.IntheUnitedStates,HCV-relatedchronicliverdiseaseisaleadingcauseoflivertransplantation.Despite
signiﬁcantimprovementsinantiviraldrugs,only ∼50%oftreatedpatientswithHCVhaveviralclearanceaftertreatment.Showing
unique species speciﬁcity, HCV has a narrow range of potential hosts infecting only chimpanzees and humans. For decades, the
chimpanzee model has been the only and instrumental primate for studying HCV infection; however, availability, economic,
and ethical issues make the chimpanzee an unsuitable animal model today. Thus, signiﬁcant research has been devoted to explore
diﬀerentmodelsthataresuitableinstudyingthebiologyofthevirusandapplicationintheclinicalresearchfordevelopingeﬃcient
and tolerable treatments for patients. This review focuses on experimental models that have been developed to date and their
ﬁndings related to HCV.
1.Introduction
Hepatitis C virus (HCV) is a small positive sense single-
strandedRNAvirusthatcausesacuteandchronichepatitisC
inhumans[1,2].HCVisoneofthemajorcausativeagentsof
liver disease worldwide, with more than 180 million people
infected [2, 3]. It is estimated that 3-4 million people are
newly infected each year [2]. In the United States, hepatitis-
C-related chronic liver disease is a leading cause of liver
transplantation and causes thousands of deaths annually [4].
Although therapeutic options are improving, viral clearance
fails in about 80% of infected patients, resulting in a chronic
viral disease [5]. In 4–20% of patients with chronic hepatitis
C, liver cirrhosis develops within 20 years, with 1–5% of
these patients developing hepatocellular carcinoma (HCC).
Persistent HCV infections are facilitated by the ability of
virus to incorporate adaptive mutations in the host and exist
as genetically distinct quasispecies. Moreover, the persistent
infection may also result from the ability of the virus to
disrupt host defense by blocking phosphorylation and func-
tion of interferon regulatory factor-3 (IRF-3), an antiviral
signaling molecule [6]. Unlike for hepatitis A and B, there
is no vaccine to prevent HCV infection; therefore, current
treatment is a combination therapy of pegylated interferon-
alpha (IFN-α) and ribavirin, which results in sustained
clearance of serum HCV-RNA. However, this treatment is
only eﬃcacious in approximately 50% of patients [7–9].
Several host factors, such as age, stage of liver ﬁbrosis, body
massindex(BMI),liversteatosis,insulinresistance,ethnicity,
and IL28B single nucleotide polymorphisms, as well as viral
genotype, can potentially inﬂuence the treatment outcome
[10, 11]. For instance, patients with HCV genotypes 2 and
3 respond more favorably to treatment than patients with
genotype 1 and 4 [12]. Therefore, new antiviral compounds
that are more eﬃcacious and better-tolerated need to be
developed.2 Journal of Biomedicine and Biotechnology
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Figure 1: HCV genome and polyprotein cleavage products. A schematic representation of the HCV genome indicating the structural
and nonstructural regions, including the 5  and 3  NTRs. The polyprotein cleavage products are drawn within. The cleavage site and the
corresponding protease are indicated (arrows).
One of the biggest challenges in developing and imple-
mentingtherapyforHCVinfectionisﬁndingtheappropriate
models to examine the translational capability. The focus of
this review emphasizes the biological importance of the virus
and discusses a number of relevant in vitro and in vivo small
animal models that are used for preclinical evaluations prior
to translating to clinical trials in humans.
2. HCVand ItsLife Cycle
HCV was originally referred to as non-A non-B Hepatitis
(NANB). In 1989, a major breakthrough in HCV research
was discovered in which the complete sequence of the viral
genomewasidentiﬁedandclonedbyChooandcollaborators
[13]. HCV is the only member of the Hepacivirus genus that
belongstotheFlaviviridaefamily[14,15].Structuralanalysis
of the virus revealed that the genetic material is surrounded
by a protective nucleocapside, composed mainly of the
protein core (C), and further protected by a lipid envelope
[16]. The lipid envelope contains two major glycoproteins,
envelope protein 1 (E1) and E2, that are embedded in the
envelope [17]. The genome consists of a single open-reading
frame (ORF), that is, ∼9,600 nucleotides long, which is
made into a single polyprotein (3,010 or 3,033 amino acids)
product (Figure 1)[ 18, 19]. The HCV genome is ﬂanked by
two nontranslated regions (NTRs), which are essential in the
replication and synthesis of viral proteins. Viral and cellular
proteases mediate the processing of the polyprotein into
structural (core, E1, E2, and p7) and nonstructural proteins
(NS2, NS3, NS4A, NS4B, NS5A, and NS5B) as illustrated in
Figure 1 [20–22]. The HCV life cycle is entirely cytoplasmic
and replication occurs mainly in hepatocytes, but the virus
may also replicate in peripheral blood mononuclear cells
(PBMCs). The virus enters the host cells through a complex
interactionbetweenvirionsandcellsurfacemoleculesCD81,
LDL receptor, scavenger receptor class B type 1 (SR-B1),
Claudin-1, and Occludin [23–26]. Recent studies by Ray et
al. and Sainz et al. have identiﬁed Niemann-Pick C1-like 1
(NPC1L1) cholesterol absorption receptor as a new HCV
entry factor [27, 28]. Once inside the cell, the virus takes
over the intracellular machinery to replicate [29]. Due to
its high-mutation rate caused by the virus’ RNA-dependent
RNA polymerase (NS5B), which lacks 3 -5  exonuclease
activity [30], HCV is considered a quasispecies composed of
6genotypeswithseveralsubtypes[12].Theelevengenotypes
have diﬀerences in geographic distribution, disease progres-
sion, and response to therapy. Genotypes 1, 2, and 3 are
distributed worldwide, with genotypes 1a and 1b accounting
for 60% of global infections. In the United States, genotypes
1a and 2b are more commonly encountered.
3.Development of AnimalModelsUsedto
Study HCV
HCV infects only humans and chimpanzees. Although the
virus was discovered more than 20 years ago using molecular
biological methods and the entire genome of the virus
sequenced, acquiring further knowledge of the virus has
been hampered by the lack of a small animal model. Much
of the understanding of HCV replication has been based
on subgenomic and genomic replicon systems developed
by Bartenschlager and colleagues, described below [31].
Viruses are obligate intracellular parasites that require a
permissive host cell in order to study replication. There-
fore, development of a suitable small animal is critical in
understanding the pathogenesis of the virus, establishing
a relevant translational platform for therapeutic methods,
and developing eﬀective vaccines. The following describes
various models used to study the pathogenicity of HCV and
its applicable progression into in vivo models, which are
summarized in Table 1.
4.Cell-Basedor In Vitro Models
Viral infection and propagation requires speciﬁc host factors
that are mainly expressed in highly diﬀerentiated cells. To
mimic the host factors in an in vitro system, development
of a cell-based model is essential. A number of cell-based
models have been established; however, most of them have
yielded limited success. Poor reproducibility and low levels
ofHCVreplicationmainlycontributetotheshortfallofthese
models. Furthermore, highly sensitive techniques are neededJournal of Biomedicine and Biotechnology 3
Table 1: In vitro and in vivo models to study HCV.
In Vitro In Vivo
Human fetal Hepatocytes Chimpanzee
Chimpanzee Hepatocytes Tree Shrew (Tupaias sp.)
Human Hepatocytes Chimeric mouse model
Peripheral Blood Mononuclear









for transcript and protein detection. Strand-speciﬁc real-
time-polymerase chain reaction (rt-PCR) was used to detect
minus-strand RNA intermediates during HCV replication;
however, due to false priming, this technique is not reliable.
As a result, several other genetic and biological indicators
are reﬁned and employed to show viral replication such as
detection of plus-strand RNA, inhibition of viral replication
using IFN-α or antisense oligonucleotides, transmission of
cell culture grown HCV to na¨ ıve cells, detection of viral
antigens by immunoﬂuorescences, and the long-term propa-
gation of HCV [22].
4.1. Primary Cell Lines. Primary cell lines obtained from
humans and chimpanzees have been used to study HCV
infection. Cultivation of HCV in tissue culture was achieved
by Iacovacci et al. in which primary fetal human hepatocytes
were injected with sera isolated from patients with HCV.
Although, these studies demonstrated an increase in copy
number of the minus-strand RNA [32, 33], the total ef-
ﬁciency after 24 days was low, expressing a maximum of
20,000copiesofRNAin106 cells.Followingasimilarstrategy
as used by Iacovacci, Lanford et al. demonstrated a rapid
increase in positive-strand RNA from days 1 to 4 and
sustained constant levels of transcripts using primary hep-
atocytes from chimpanzees [34]. Using strand-speciﬁc rt-
PCR, the authors detected minus-strand RNA replication
intermediates, which indicate that the virus is undergoing
replication within the hepatocytes. In addition, they showed
that primary liver cells obtained from baboons could not
be used to cultivate the virus. This observation supports the
concept that HCV is quite species selective and has a narrow
range of hosts. In 1999, Rumin et al. developed speciﬁc
tissue culture conditions that could support the culturing of
primary human hepatocytes for 4 months, without any
morphogenicchanges[35].Althoughtheywereabletodetect
increasing levels of RNA during the 3 months of culturing,
the eﬃciency had many uncontrollable parameters such as
the infectivity of the sera and the quality of the hepatocytes.
In addition to the potential to infect hepatocytes, HCV has
also been shown to replicate in PBMCs, indicating its ability
to replicate in extrahepatic cells [35]. Consistent with this
observation, HCV has been reported to replicate within
PBMCsisolatedfromchronicallyinfectedpatients.Cribieret
al. reported detection of viral RNA 28 days after infecting a
mixture of white blood cells (obtained from 10 donors) that
were infected in vitro with high-titer serum [36]. However,
the levels and quality of RNA were similar to those reported
in hepatocytes.
4.2. Nonprimary Cell Lines. The most critical shortfalls in
culturing primary cell lines have been the availability and
the technical challenges associated with culturing these cells
in vitro. As a result, tremendous eﬀorts have been made in
developing a nonprimary cell line that is able to mimic phys-
iological hepatocytes. Although a number of cell lines have
been tested to show persistent replication, the most extensive
studies have been conducted with the non-neoplastic cell
line PH5CH, which was obtained from a human hepatocyte
immortalized with the simian virus 40 large T antigen.
Two important studies by Ikeda et al. and Kato et al. have
shown that HCV plus-strand RNA can be detected more
than 100 days after infection with HCV [37, 38]. In addition,
they determined that only certain variants, variants in the
hypervariable region 1 (HVR1) of the E2 protein, could
infect and replicate in PH5CH cells. More importantly, these
two groups demonstrated that infected PH5CH cells treated
with IFN-α showed signiﬁcant loss of plus-strand RNA of
the virus; thereby, it can serve as an ideal in vitro platform
to examine potential therapeutic molecules.
In addition to nonneoplastic cell lines, human B- and
T-cell lines have been used as in vitro model to study HCV
infection. Mizutani et al. using the T-cell line MT2 isolated
a clone containing HCV RNA after 200 days postinfection
[39]. Moreover, T- and B-cell lines; HPB-Ma and Daudi,
respectively, have been shown to sustain virus propagation
lasting for more than one year [40]. A study by Shimizu et
al. has demonstrated that supernatant from HCV infected
Daudi cells exhibited remarkable infectious capacity in
chimpanzee [41]. HCV RNA was detected in the chimpanzee
serum after 5 weeks postinfection, however, the levels of
HCV replication in the infected animal were low and
gradually disappeared after 25 weeks postinfection.
5.TransfectedCellLines
5.1. Cloned HCV Genomes. Generation of clones from the
HCV genome has permitted the genetic analysis of a variety
of diﬀerent aspects in the HCV life cycle. Introduction of
cloned virus genome is superior to infection using HCV
infected patient serum because the clone is well deﬁned and
can be generated in high quantities. Studies by Dash et al.
andYooetal.haveshownthattransfectingHepG2andHuH-
7, respectively, with truncated HCV genomes that lacked
the 3  NTR were able to maintain extended culture infected
with HCV [42, 43]. However, the usage of this truncated
genome contradicts the ﬁnding that the 3  NTR is essential
forreplicatinginvivo[44,45].Inaddition,thismethodisnot4 Journal of Biomedicine and Biotechnology
useful in infecting chimpanzee with HCV producing cells,
unlike other transfected cell methods.
5.2. Subgenomic Replicons. In 1999, Bartenschlager et al. de-
veloped a system that consisted of subgenomic replicons of
HCV that could replicate autonomously in hepatic cell cul-
tures [31, 46]. To obtain the subgenomic replicons, they
isolated sera from patients infected with HCV and puriﬁed
the viral genome. Complementary DNA was synthesized and
ampliﬁed; therefore, the ﬁnal clones selected contained the
complete genome including the 5  and 3  NTR, which was
stably expressed in the pCR2.1 expression vector containing
a T7 promoter. The ﬁnal replicon contained a gene resistant
to neomycin and the region encoding the structural proteins
was eliminated. The structural proteins were removed from
this replicon because it was previously observed that for sev-
eral plus-strand RNA viruses did not require the structural
proteins for RNA replication [47–49]. This replicon was able
to replicate itself within the cell; however, it was not capable
of producing infectious viruses. In addition, this replicon
w a sa b l et or e p r o d u c ei nH u H - 7c e l l sw i t hh i g he ﬃciency
and for an extended period of time [50]. Studies have also
been conducted to determine if certain mutations improve
replication. It was determined that mutations in the NS5a
regionandintheNS4bregionincreasereplicationmorethan
1,000 times [51, 52].
Subgenomes of other genotypes of HCV have been
showntobeeﬃcientinmaintaininghighinfectiouspotential
and long-term in vitro culture, for example, genotype 2a
clone isolated from a Japanese patient with a rare case of
fulminant hepatitis C, designated as JFH-1 (Japanese ful-
minant hepatitis C). The data have indicated the isolate
could replicate in HuH-7 cells without the requirements for
adaptive mutations that were required for previous isolates
[53]. HuH-7 cells infected with cloned JFH-1 genomes pro-
duced viruses (designated as HCVcc for cell culture derived
HCV) that were capable of infecting na¨ ıve HuH-7 cells [54].
In addition, the virus particles could be neutralized with a
monoclonal antibody against the viral glycoprotein E2 [55].
The study was the ﬁrst in vitro experiment that showed the
complete lifecycle of HCV. More importantly, virus obtained
from the cell culture was highly infectious in vivo by readily
infecting chimpanzees [54, 56]a sw e l la si m m u n o d e ﬁ c i e n t
mice with partial human livers (chimeric mice) described
later [56].
In addition to HuH-7 cells supporting propagation of
HCVcc, additional cell lines have been developed. Human
hepatoma Li23-derived cells were found to possess the nec-
essary components required for HCV RNA replication
and persistent production of infectious HCV [57]. Similar
expression levels of HCV entry factors were observed be-
tween Li23- and HuH-7-derived cells, suggesting that certain
factors are necessary for infectivity and propagation of
HCVcc. Recent studies have shown that expression of a liver-
speciﬁc microRNA, miR-122, in HEp3B cells can propagate
HCVcc [58]. A lentiviral vector expressing miR-122 was
placed in HEp3B cells at comparable levels with HuH-7 cells,
which lead to the production of infectious particles. The
levels were comparable to those observed in HuH-7-infected
cells. Shimakami et al. have shown that miR-122 forms a
complex with Ago2 to protect and stabilize HCV RNA from
5  exonuclease activity of the host mRNA decay machinery
[59]. This ﬁnding may explain why expression of miR-122 in
HEp3B cells can support HCV propagation.
6. AnimalModel
6.1. Chimpanzees. The chimpanzee animal model (Pan trog-
lodytes) is currently the only established animal or primate
model for HCV infection. The chimpanzee model for HCV
infection was instrumental in the initial studies of non-A,
non-Bhepatitis,includingobservationsontheclinicalcourse
of infection, determination of the physical properties of the
virus,andeventualcloningoftheHCVnucleicacid[60].The
chimpanzee model has been invaluable in demonstrating
thatthecDNAclonesofHCVdevelopedfromHCVstrainsof
genotypes 1a, 1b, and 2a were infectious. In addition, using
this primate model that is evolutionarily close and associated
with humans has provided important insight regarding the
etiology of liver disease caused by HCV. The chimpanzee
has provided evidence that infection with HCV did not
providecompleteprotectiveimmunitywhenchallengedwith
homologous or heterologous viral strains [61, 62]. As a
result, it has been diﬃcult to design eﬀective vaccines against
the virus, even though chimpanzees have allowed for the
identiﬁcation of important viral genetic elements. Several
studies have identiﬁed the importance of the active sites of
various enzymatic functions as well as the role of the p7
protein. Thus, chimpanzees are certainly one of the ideal
models to study the pathogenesis of the HCV and serve as
a great model for translation research; however, it is quite a
challenge to work with this model due to limited availability,
the costs associated with acquiring and maintaining the
animal for scientiﬁc research, and public resistance.
6.2. Tupaias. The tree shrew, Tupaias (T. belangeri chinen-
sis), was previously shown to be susceptible to the hepatitis B
virus [63, 64]. Xie et al. have demonstrated that Tupaia were
susceptible to HCV infection [65]. However, persistent HCV
infection could not be established and only 25% of infected
animals developed transient or intermittent viremia. In
addition, Tupaia must undergo severe immunosuppression
before they can be infected with HCV. However, sera or
plasmas obtained from patients with HCV were able to
infect primary Tupaia hepatocyte cultures [66]. The authors
demonstrated that the hepatocytes could produce infectious
viruses that were capable of infecting na¨ ıve hepatocytes.
Sequence analysis of cloned Tupaia cDNA revealed a high
degree of homology between Tupaia and human CD81 large
extracellular loops (LELs), suggesting CD81 aids in viral
entry. In addition, the study indicated that viral entry can
also occur through receptors other than CD81 since cellular
binding of E2 and anti-CD81 antibodies or soluble CD81-
LEL could not inhibit HCV infection.
6.3. Chimeric Human Liver Mouse Model. By genetically
manipulating the uPA transgenic mouse, Mercer et al. have
generated a chimeric mouse model with human hepatocytes.Journal of Biomedicine and Biotechnology 5
This was done by transplanting normal human hepatocytes
into severe combined immunodeﬁciency (SCID) mice car-
rying a plasminogen activator transgene [67]. The human
hepatocytes transplanted were able to integrate into the
parenchymaandrepopulatethediseasedmouseliverwithout
losing their metabolic functions. Successfully generated
chimeric mice exhibited prolonged infection with high viral
titers following inoculation with HCV and HBV isolated
from human serum. In addition, the authors have demon-
strated that the model was able to exhibit horizontal trans-
mission in which HCV can be transmitted from one infected
animal to another. Since the mice were immunodeﬁcient,
they were not appropriate models to study HCV patho-
genesis, although they were useful in assessing the activity
of antiviral compounds, speciﬁcally the eﬀect of IFN-α,
HCV protease inhibitors and cyclophilin inhibitor DEBIO-
025 on virus propagation and infectivity [68]. Moreover,
this chimeric mouse model has been used to show that
neutralizing antibodies can prevent an HCV infection in vivo
[69].
6.4. Genetically Humanized Mouse Model. Studies by Ploss et
al. have previously shown that CD81 and occludin (OCLN)
were the minimum human factors required for HCV uptake
by rodent cells [70]. To determine these human factors for
eﬃcient HCV infection, the authors constructed recombi-
nantadenovirusexpressinghumanCD81,scavengerreceptor
type B class 1 (SCARB1), claudin 1 (CLDN1), and OCLN.
Inoculating mice with these human factors expressed in
adenoviral vector was suﬃcient for HCV infection [71]. Fur-
thermore, the authors employed a bicistronic HCV genome
expressing CRE recombinase (Bi-nlsCre-Jc1FLAG2, abbre-
viated HCV-CRE), which activates a loxP-ﬂanked luciferase
reporter in Rosa26-Fluc mice. The mice were infected with
the HCV-CRE and the mice that were expressing all four
transgenes had luciferase signal that peaked at 72 hours
postinfection. Interestingly, only animals that expressed both
human CD81 and OCLN displayed 6–10 fold increase
in virus infection. In addition, they were also able to
show that SCARB1 is a legitimate HCV entry factor. This
system allows for the studies of HCV coreceptor biology
in vivo and evaluation of passive immunization strategies.
This, therefore, represents the ﬁrst immunocompetent small
animal model for HCV study.
7. Conclusions
Although, great strides in small animal models for the study
of HCV have been made in the past decades, HCV remains
a global public health issue. In past years, advancements
have been made in vitro and in vivo models for the study
of hepatitis C, in particular, the chimeric and genetically
humanized mouse models, which have provided a platform
tostudynewantiviraltreatmentsandevaluateimmunization
strategies. With the advent of autoantibodies recognizing
structural proteins found in HCV patients, both in vitro and
in vivo models could provide an important foundation for
the discovery of novel biomarkers for prognosis and treat-
ment [72, 73]. With new insights on HCV biology obtained
from in vitro models and the ability to infect animals with
active immune systems, it should be possible to develop new
therapies and possibly a vaccine for HCV.
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